Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Semaglutide 2· 4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Open access

Abstract

BACKGROUND: Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at high risk of liver-related and all-cause morbidity and mortality. We investigated the efficacy and safety of the glucagon-like peptide-1 analogue semaglutide in patients with NASH and compensated cirrhosis. METHODS: or more were randomly assigned (2:1) to receive either once-weekly subcutaneous semaglutide 2·4 mg or visually matching placebo. Patients were randomly allocated via an interactive web response system, stratified by presence or absence of type 2 diabetes. Patients, investigators, and those assessing outcomes were masked to treatment assignment. The primary endpoint was the proportion of patients with an improvement in liver fibrosis of one stage or more without worsening of NASH after 48 weeks, assessed by biopsy in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study drug. The trial is closed and completed, and registered with ClinicalTrials.gov, number NCT03987451. FINDINGS: (SD 5·9); 53 (75%) patients had diabetes. 47 patients were randomly assigned to the semaglutide group and 24 to the placebo group. After 48 weeks, there was no statistically significant difference between the two groups in the proportion of patients with an improvement in liver fibrosis of one stage or more without worsening of NASH (five [11%] of 47 patients in the semaglutide group vs seven [29%] of 24 in the placebo group; odds ratio 0·28 [95% CI 0·06-1·24; p=0·087). There was also no significant difference between groups in the proportion of patients who achieved NASH resolution (p=0·29). Similar proportions of patients in each group reported adverse events (42 [89%] patients in the semaglutide group vs 19 [79%] in the placebo group) and serious adverse events (six [13%] vs two [8%]). The most common adverse events were nausea (21 [45%] vs four [17%]), diarrhoea (nine [19%] vs two [8%]), and vomiting (eight [17%] vs none). Hepatic and renal function remained stable. There were no decompensating events or deaths. INTERPRETATION: In patients with NASH and compensated cirrhosis, semaglutide did not significantly improve fibrosis or achievement of NASH resolution versus placebo. No new safety concerns were raised. FUNDING: Novo Nordisk A/S.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(23)00068-7

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1: Trial profile
Figure 1: Trial profileCC BY-NC-ND · PubMed Central
Figure 2: Improvement in liver fibrosis and no worsening of NASH (A) and resolution of NASH (B) at 48 weeks p-values are two-sided and taken from a Cochran–Mantel–Haenszel test stratified by baseline diabetes status. Patients with missing outcomes were imputed as non-responders. NASH=non-alcoholic steatohepatitis. OR=odds ratio.
Figure 2: Improvement in liver fibrosis and no worsening of NASH (A) and resolution of NASH (B) at 48 weeks p-values are two-sided and taken from a Cochran–Mantel–Haenszel test stratified by baseline diabetes status. Patients with missing outcomes were imputed as non-responders. NASH=non-alcoholic steatohepatitis. OR=odds ratio.CC BY-NC-ND · PubMed Central
Figure 3: Change in imaging parameters and liver enzymes from baseline to week 48 Liver stiffness assessed by MRE (A), liver steatosis assessed by MRI-PDFF (B), ALT (C), and AST (D). Number of observations per treatment group and visit is presented in the lower part of each plot. Error bars show the SE of the mean for observed values. ALT=alanine aminotransferase. ANCOVA=analysis of covariance. AST=aspartate aminotransferase. ETR=estimated treatment ratio. MRE=magnetic resonance elastography. MRI-PDFF=MRI proton density fat fraction. *ETRs with 95% CI and two-sided p-values were calculated using the same ANCOVA analysis. Missing data were imputed from the observed data in the placebo group using the same ANCOVA model but without treatment as factor.
Figure 3: Change in imaging parameters and liver enzymes from baseline to week 48 Liver stiffness assessed by MRE (A), liver steatosis assessed by MRI-PDFF (B), ALT (C), and AST (D). Number of observations per treatment group and visit is presented in the lower part of each plot. Error bars show the SE of the mean for observed values. ALT=alanine aminotransferase. ANCOVA=analysis of covariance. AST=aspartate aminotransferase. ETR=estimated treatment ratio. MRE=magnetic resonance elastography. MRI-PDFF=MRI proton density fat fraction. *ETRs with 95% CI and two-sided p-values were calculated using the same ANCOVA analysis. Missing data were imputed from the observed data in the placebo group using the same ANCOVA model but without treatment as factor.CC BY-NC-ND · PubMed Central
Figure 4: Change in (A) bodyweight and (B) HbA1c (in patients with type 2 diabetes) from baseline to week 48 Number of observations per treatment group and visit is presented in the lower part of each plot. Error bars show the SE of the mean for observed values. ANCOVA=analysis of covariance. ETD=estimated treatment difference. *ETDs with 95% CI and two-sided p-values were calculated using the same ANCOVA analysis. Missing data were imputed from the observed data in the placebo group using the same ANCOVA model but without treatment as factor.
Figure 4: Change in (A) bodyweight and (B) HbA1c (in patients with type 2 diabetes) from baseline to week 48 Number of observations per treatment group and visit is presented in the lower part of each plot. Error bars show the SE of the mean for observed values. ANCOVA=analysis of covariance. ETD=estimated treatment difference. *ETDs with 95% CI and two-sided p-values were calculated using the same ANCOVA analysis. Missing data were imputed from the observed data in the placebo group using the same ANCOVA model but without treatment as factor.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 533

Metadata

Authors
Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., & Newsome, P. N.
Affiliations
  • University of California San Diego (US)
  • Mayo Clinic (US)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • Novo Nordisk (Denmark) (DK)
  • The University of Texas at San Antonio Health Science Center (US)
  • Sorbonne Université (FR)
  • Virginia Commonwealth University (US)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2023-06
Volume
8
Issue
6
Pages
511-522
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
OpenAlex
W4327558235
Cited by
533
References
32
Citations by year
2026: 141 · 2025: 185 · 2024: 146 · 2023: 60
FWCI
105.75
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet. Gastroenterology & hepatology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK120515, R01DK106419, R01DK121378, R01DK124318, U01DK061734, U01DK130190)
  • National Center for Advancing Translational Sciences (5UL1TR001442)
  • National Institute for Health and Care Research
  • Novo Nordisk
  • Birmingham Biomedical Research Centre
  • National Heart, Lung, and Blood Institute (P01HL147835)
  • National Institute on Alcohol Abuse and Alcoholism (U01AA029019)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
semaglutide, GLP-1 receptor agonists, nonalcoholic steatohepatitis, compensated cirrhosis, liver fibrosis, NASH resolution, type 2 diabetes, adverse events, nausea, drug safety, liver disease treatment, GLP-1 receptor antagonists
MeSH terms
Semaglutide, Adult, Diabetes Mellitus, Type 2, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide 2· 4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. https://app.cochat.ai/papers/10.1016/s2468-1253(23)00068-7
The paper
Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., & Newsome, P. N. (2023). Semaglutide 2· 4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(23)00068-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.